Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 7/1999

01-07-1999

Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells

Authors: Pamarthi M. Mohan, Sajani S. Lakka, Sanjeeva Mohanam, Yoshiaki Kin, Raymond Sawaya, Anthanassios P. Kyritsis, Garth L. Nicolson, Jasti S. Rao

Published in: Clinical & Experimental Metastasis | Issue 7/1999

Login to get access
Metadata
Title
Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells
Authors
Pamarthi M. Mohan
Sajani S. Lakka
Sanjeeva Mohanam
Yoshiaki Kin
Raymond Sawaya
Anthanassios P. Kyritsis
Garth L. Nicolson
Jasti S. Rao
Publication date
01-07-1999
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 7/1999
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1006779902978

Other articles of this Issue 7/1999

Clinical & Experimental Metastasis 7/1999 Go to the issue

OriginalPaper

Expression of matrix metalloproteinases and their inhibitors in human brain tumors

OriginalPaper

Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan

OriginalPaper

Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model

OriginalPaper

Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands

OriginalPaper

Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate

OriginalPaper

bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits